Workshop: Environmental Dimensions of AMR

Full focus on the impact of environment on AMR when a global group of scientist collaborated during two intense days. Themes discussed: Evolution, Transmission and Interventions. The purpose of the workshop was to explore and identify critical research needs that relate to the environmental dimensions of AMR, both in the longer term for providing input to an updated JPIAMR Strategic Research Agenda, but also in the shorter term to provide guidance for specific calls. Creating more insights on  what role environment plays for antibiotic resistance. We can not exclude the importance of environmental dimensions from the complex context of AMR.

Please, find an article about the report of the outcomes from the workshop.

The workshop in Gothenburg was hosted together with CARe – Centre for Antibiotic Resistance Research at University of Gothenburg.

We made a few interviews during the workshop, please view the videos below.

We say thank you to all of you who participated!

New WHO Report: Current Clinical Pipeline Insufficient

The WHO review shows that the current clinical pipeline is still insufficient to mitigate the threat of antimicrobial resistance.

JPIAMR contributes to finding solutions to the challenges presented by WHO. JPIAMR is processing current and future calls that funds research on the very challenges highlighted in the report. Among with several ground breaking activities.

WHO points out:

  • More investments needed in basic science, drug discovery and clinical development.
  • Most of the agents in the pipeline are modifications of existing antibiotic classes. They are only short term solutions as they usually cannot overcome multiple existing resistance mechanisms and do not control the growing number of pan-resistant pathogens.
  • More innovative products are required against pathogens with no cross- or co-resistance to existing classes.
  • Although oral formulations for community diseases associated with high morbidity are essential globally, few oral antibiotics for infections caused by Gram-negative pathogens are in the pipeline.

As of May 2017, a total of 51 antibiotics (including combinations) and 11 biologicals were in the clinical pipeline with 42 new therapeutic entities (33 antibiotics and nine biologicals) that target priority pathogens, seven products for tuberculosis (TB) and nine for C.difficile infections (seven antibiotics and two biologicals) . The qualitative analysis shows a lack of potential treatment options for priority resistant bacteria, especially for multidrug- and extensively drug-resistant Gram-negative pathogens.

The full report is now available,  please click here to view it.

India, South Africa and Egypt are New Members of JPIAMR

JPIAMR Becomes Global Collaborative Platform on Antimicrobial Resistance

On 29 June 2017, India, South Africa and Egypt was accepted as a new members of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). Now 26 countries are members of the global collaborative platform and involved in the mission to curb antimicrobial resistance (AMR).

” Antimicrobial Resistance is a serious threat that must be acted on globally, and we are delighted to expand the collaborative platform to include India, South Africa and Egypt” said Carlos Segovia, Chair of the JPIAMR Management Board. “Having India as a member means that the world’s second largest country acknowledges JPIAMR as a key platform for harnessing antimicrobial resistance. With South Africa and Egypt as active members participating in calls, that shows they too believe in JPIAMR as a unique global platform that truly advances AMR research and results. We welcome their capacities and capabilities to further strengthen and define the common Strategic Research Agenda that members of JPIAMR develop. Now we all work together”, concludes Segovia.

The new EC Action Plan on AMR outlines JPIAMR as a key mechanism for global collaboration, coordinating calls and for aligning a strategic research agenda to tackle AMR. Now JPIAMR is a global platform were countries come together as members because they trust the organisation. Member countries wants to be part of multilateral calls and there is no other platform on AMR, in the world.

For more information, please contact the JPIAMR secretariat at the Swedish Research Council in Stockholm.

Download: Press Release JPIAMR New Members to Global Platform on AMR 170629.

Point of contact for media inquiries:

Mr. Anders Bjers, Communications Manager JPIAMR

E-mail: anders.bjers@vr.se

Direct: +46-8-546 44 068

Mobile: +46-73-344 03 77

 

 

20 Transnational Research Projects enters next step of fifth Call

Now twenty transnational research projects are invited to submit full applications within the JPIAMRs fifth Joint Call on Prevention and Intervention Strategies to control AMR infections.

Earlier this year the JPIAMR announced its fifth joint call on “Prevention and Intervention Strategies to control AMR infections”. As the deadline for submitting a pre-proposal passed on March 21st, 53 transnational consortia had submitted applications. After evaluation by a panel of international reviewers, twenty of the projects have been invited to submit a full application. The deadline for the full application is on July 4th. For more information, please visit the call page.

Facts about the fifth joint call:

The JPIAMR, in partnership with fifteen countries: Belgium, Canada, Czech Republic, Germany, Ireland, Israel, Italy, Latvia, Netherlands, Norway, Poland, Romania, Spain, Sweden and Switzerland, launched a fifth joint call for transnational research Projects.

The call targets research in the following topic:

Comparison of prevention, control and intervention strategies for AMR infections through multidisciplinary studies, including One Health approaches.

G20 Health Ministers Points Out JPIAMR as Key Initiative to Support

When the G20 Health Ministers recently met in Germany, AMR was at the very top of their agenda. Germany who holds the G20 presidency described it as an” important breakthrough”, that all nations agreed to address the growing antibiotic resistance in the world.

In the declaration from the meeting, the G20 Health Ministers pointed out JPIAMR as one of the key initiatives to support, by concluding “we commit to broaden the voluntary financial support for these initiatives. We call on other countries, philanthropic organizations, academia and the private sector to support these initiatives”.

JPIAMR support new evidence and innovations that reduce the burden of antimicrobial resistance through coordinated global collaborative research in Europe and around the world. Also aiming to undertake further research to better understand how resistance develops and spreads in the environment. And to develop diagnostic tools and better surveillance methods as well as validating smarter strategies for using antibiotics in healthcare and agriculture. Today 24 countries have joined JPIAMR as members. The collaborative platform is now internationally recognized.

Please follow this link to read the whole statement from the G20 Health Minister meeting in Germany on May 19, 2017. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/G/G20-Gesundheitsministertreffen/G20_Health_Ministers_Declaration_engl.pdf

AMR Call from Southeast Asia – Europe Joint Funding Scheme for Research and Innovation (SEA-EU-NET)

AMR Call from Southeast Asia – Europe Joint Funding Scheme for Research and Innovation (SEA-EU-NET)

The JPIAMR members Belgium, France, Germany, Poland, Spain, Sweden, Switzerland, and Turkey participate in a joint call with the South-East Asian countries Cambodia, Lao PDR, The Phillipines, Thailand, and Vietnam within the framework of the EU-funded project SEA-EU-NET.

The call cover over the thematic areas of Health (Anti-microbial drug resistance, Emerging infectious diseases), Environment/ Climate Change (Adaptation/Resilience of food production systems, Impacts of Climate Change on Ecosystems/Biodiversity) with aim to enhance bi-regional co-operation and develop new partnerships as well as strengthen existing ones.

Deadline for submission: 30 June 2017, 18.00 CET

For more information on the call and application, please see:

Southeast Asia – Europe Joint Funding Scheme for Research and Innovation

Ireland joins international initiative to tackle Antimicrobial Resistance

On 28 March 2017, Ireland was accepted as a new member of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). It means that now 16 EU countries, and 23 countries worldwide, are involved in the international mission to fight Antimicrobial Resistance. Ireland will be represented in JPIAMR by the Health Research Board, the nation’s lead agency responsible for supporting and funding health research, information and evidence.

Since penicillin was discovered 90 years ago, bugs have developed resistance to penicillin and other antibiotics. The latest World Health Organisation report shows that there is an increasingly high level of antibiotic resistance in all regions of the world. This will severely affect people when antibiotics no longer work.

” Antimicrobial Resistance (AMR) is a grave issue that must be tackled globally, and we are delighted to expand the group to include Ireland,” said Carlos Segovia, Chair of the JPIAMR Management Board. “The aim of this Joint Programme is to reduce AMR by supporting scientific activities at an international level to generate evidence-based solutions that provide policies for public health including veterinarian and agricultural levels. By working together, we hope to mobilise existing and new resources amongst JPIAMR members. The Joint Initiative approach allows us to coordinate, prioritise, and channel research activities to where the potential for benefit to everyone is the greatest”.

“Antibiotic resistance poses a public health threat on a global scale. It is a major societal challenge that a national research programme cannot tackle effectively alone,” said Dr Mairead O’Driscoll, Interim Chief Executive at the Health Research Board (HRB), Dublin.” Ireland has some strong research experience in this area, but bacteria don’t exactly respect borders so it makes perfect sense for us joining forces with other countries to develop critical mass in this area and attract new researchers to the area.”

Ireland’s action on Antimicrobial Resistance (AMR)

Ireland has a good track record in addressing antimicrobial resistance with prevention and control of health care associated infections (HCAIs) and AMR being a significant long standing patient safety and public health priority for the Irish Department of Health.

A National Interdepartmental AMR Consultative Committee was set up in 2014 between the Department of Health and the Department of Agriculture, Food and the Marine. The objective was to raise public and professional awareness of the threat of AMR to both public and animal health, addressing the repercussions for human health, agriculture, food industry and environment.

Another initiative which the Health Services Executive has established in Irish acute public hospitals is good systems for recording and benchmarking antimicrobial prescribing, and for recording and comparing antimicrobial resistance rates for serious infections with other European countries. Ireland also has an established national system for reporting on antibiotic consumption in the community.

Ireland has contributed to reporting to the European Antimicrobial Resistance Surveillance System since 1999 and through its membership of the World Health Organisation, is part of the international effort aimed at tackling the global public health treat of AMR.

Examples of Irish research in the area of AMR, funded by the Health Research Board (HRB)

  • Overprescribing
    Professor Andrew Murphy and his staff at National University of Ireland, Galway (NUI Galway) has found that almost half of the patients in General Practice were prescribed antibiotics for common ailments like coughs and colds – which were not necessary. This was driven by public insistence that they leave the doctor’s office with something, having paid for the appointment. The study showed there is a need for a change of attitude amongst doctors and patients to reduce overprescribing of antibiotics. To improve public understanding the team has developed an app game explaining which illnesses really require antibiotics.
  •  Clean medical devices
    Pioneering work from professor James O. Gara at NUI Galway, has led to a discovery about how bacteria cling to the surfaces of medical devices, providing potential to reduce infections from devices like catheters inserted into the body.

ABOUT JPIAMR:

The Joint Programming Initiative on Antimicrobial Resistance, JPIAMR, coordinates national funding and supports collaborative action for filling knowledge gaps on AMR.

By 2050, 10 million people each year are predicted to die as a result of drug resistant infections. Therefore, we must focus on reducing the incidence of bacterial infectious disease, ensuring rational use of the remaining antibiotics and reducing transmission of resistant bacteria. We must also undertake further research to better understand how resistance develops and spreads in the environment.

23 countries have joined forces to develop scientific proposals according to a common Strategic Research Agenda.

utveckling.jpiamr.eu

About the HRB:

The Health Research Board (HRB) is the lead agency in Ireland responsible for supporting and funding health research, information and evidence. The vision is Healthy people through excellent research and applied knowledge.

www.hrb.ie

 

 

 

 

 

 

 

 

 

 

 

 

Laura Piddock new Chair of the JPIAMR Scientific Advisory Board

We are pleased to announce Laura Piddock, Professor of Microbiology, at the Institute of Microbiology and Infection, University of Birmingham, as the new Chair of the JPIAMR Scientific Advisory Board.

Laura Piddock was elected as Chair by the Scientific Advisory Board at their meeting earlier this month. The Management Board will ratify her position in our next meeting in Canada.

Read here for more information about Laura Piddock.

For further information about the work of Laura’s team, please see the Antimicrobials Research Group website: http://www.antimicrobialagentsresearchgroup.com/